Drug Profile
Research programme: female genitourinary therapeutic - Evestra
Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Evestra
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Genitourinary disorders
Most Recent Events
- 28 May 2021 No recent reports of development identified for research development in Genitourinary-disorders in USA
- 06 Apr 2017 Early research in Genitourinary disorders in USA (unspecified route)
- 06 Apr 2017 Female genitourinary therapeutic licensed to Gedeon Richter in certain territories outside USA